TABLE 2.

Clinical comparisons

	Observed mean (years) (N = 20)	Model coefficient (years) (N = 19)	95% CI	p‐value
Age at onset
Mutation groupa				p = 0.06
APP vs PSEN1 pre‐codon 200a	51.5 vs 41.6	8.8	1.5, 16.1	p = 0.02*
APP vs PSEN1 post‐codon 200a	51.5 vs 46.5	5.9	−2.0, 13.8	p = 0.13
PSEN1 pre‐codon 200 vs PSEN1 post‐codon 200a	41.8 vs 46.5	−2.9	−9.4, 3.6	p = 0.35
Females vs malesb	42.0 vs 49.6	−7.3	−13.1, −1.4	p = 0.02*
APOE4 carrier vs non‐carrierc	46.3 vs 44.8	3.5	−2.5, 9.5	p = 0.23
Disease duration
Mutation groupa				p = 0.73
APP vs PSEN1 pre‐codon 200a	9.6 vs 9.8	0.7	−3.1, 4.4	p = 0.71
APP vs PSEN1 post‐codon 200a	9.6 vs 11.5	−0.6	−4.6, 3.5	p = 0.77
PSEN1 pre‐codon 200 vs PSEN1 post‐codon 200a	9.3 vs 11.5	−1.2	−4.6, 2.1	p = 0.44
Females vs malesb	10.6 vs 9.6	−0.2	−3.2, 2.8	p = 0.89
APOE4 carrier vs non‐carrierc	13.6 vs 8.0	5.4	2.4, 8.5	p = 0.002**

Observed mean for whole cohort (N = 20), except for APOE where N = 19. Linear regression models compared age at onset and disease duration by mutation subgroup, sex and APOE4 status (N = 19). Asterisks represent statistically significant correlations.

^a Adjusted for sex and APOE genotype.

^b Adjusted for mutation sub‐group and APOE genotype.

^c Adjusted for mutation sub‐group and sex.

^* p < 0.05

^** p < 0.01.